Selective, nontoxic CB2 cannabinoid o-quinone with in vivo activity against triple-negative breast cancer

Journal of Medicinal Chemistry

Volumn 58, Issue 5, 2015, Pages 2256-2264

  Morales, Paula ^a   Blasco Benito, Sandra ^b,c   Andradas, Clara ^b,c   Gómez Cañas, María ^b   Flores, Juana María ^b   Goya, Pilar ^a   Fernández Ruiz, Javier ^b   Sánchez, Cristina ^b,c   Jagerovic, Nadine ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c Universidad Complutense   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

7 (1',1' DIMETHYLHEPTYL) 1 ETHYL 1,4 DIHYDRO 4,4 DIMETHYLCHROMENO[4,3 C]PYRAZOLE 8,9 DIONE; 7 (1',1' DIMETHYLHEPTYL) 1,4 DIHYDRO 4,4 DIMETHYLCHROMENO[4,3 C]PYRAZOLE 6,9 DIONE; 7 (1',1' DIMETHYLHEPTYL) 1,4 DIHYDRO 4,4 DIMETHYLCHROMENO[4,3 C]PYRAZOLE 8,9 DIONE; 7 (1',1' DIMETHYLHEPTYL) 2,4 DIHYDRO 4,4 DIMETHYLCHROMENO[4,3 C]PYRAZOLE 6,9 DIONE; 7 (1',1' DIMETHYLHEPTYL) 2,4 DIHYDRO 4,4 DIMETHYLCHROMENO[4,3 C]PYRAZOLE 8,9 DIONE; ANTINEOPLASTIC AGENT; CANNABINOID 2 RECEPTOR; CANNABINOID QUINONE; CASPASE 3; UNCLASSIFIED DRUG; 7-(1',1'-DIMETHYLHEPTYL)-1-ETHYL-1,4-DIHYDRO-4,4-DIMETHYLCHROMENO(4,3-C)PYRAZOLE-8,9-DIONE; BENZOPYRAN DERIVATIVE; BENZOQUINONE; BENZOQUINONE DERIVATIVE; CANNABINOID; MESSENGER RNA; PYRAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST EPITHELIUM CELL; DRUG RECEPTOR BINDING; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; OXIDATIVE STRESS; TRIPLE NEGATIVE BREAST CANCER; WESTERN BLOTTING; ANIMAL; BREAST; CELL CULTURE; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENETICS; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNTHESIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOPYRANS; BENZOQUINONES; BLOTTING, WESTERN; BREAST; CANNABINOIDS; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; HUMANS; MICE; MICE, NUDE; PYRAZOLES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, CANNABINOID, CB2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924709736     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00078     Document Type: Article

References (50)

1. Tramer, M. R.; Carroll, D.; Campbell, F.; Reynolds, D. J.; Moore, R.; McQuay, H. J. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review Br. Med. J. 2001, 323, 16-21
2. Sharkey, K. A.; Darmani, N. A.; Parker, L. A. Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system Eur. J. Pharmacol. 2014, 722, 134-146
3. Cridge, B. J.; Rosengren, R. J. Critical appraisal of the potential use of cannabinoids in cancer management Cancer Manage. Res. 2013, 5, 301-313
4. Velasco, G.; Sánchez, C.; Guzmán, M. Towards the use of cannabinoids as antitumour agents Nat. Rev. Cancer 2012, 12, 436-444
5. Guzmán, M. Cannabinoids: potential anticancer agents Nat. Rev. Cancer 2003, 3, 745-755
6. Chakravarti, B.; Ravi, J.; Ganju, R. K. Cannabinoids as therapeutic agents in cancer: current status and future implications Oncotarget 2014, 5, 5852-5872
7. Guindon, J.; Hohmann, A. G. The endocannabinoid system and cancer: therapeutic implication Br. J. Pharmacol. 2011, 163, 1447-1463
8. Van Dross, R.; Soliman, E.; Jha, S.; Johnson, T.; Mukhopadhyay, S. Receptor-dependent and receptor-independent endocannabinoid signaling: a therapeutic target for regulation of cancer growth Life Sci. 2013, 92, 463-466
9. Caffarel, M. M.; Sarrió, D.; Palacios, J.; Guzmán, M.; Sánchez, C. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation Cancer Res. 2006, 66, 6615-6621
10. Ligresti, A.; Moriello, A. S.; Starowicz, K.; Matias, I.; Pisanti, S.; De Petrocellis, L.; Laezza, C.; Portella, G.; Bifulco, M.; Di Marzo, V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma J. Pharmacol. Exp. Ther. 2006, 318, 1375-1387
11. Shrivastava, A.; Kuzontkoski, P. M.; Groopman, J. E.; Prasad, A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy Mol. Cancer Ther. 2011, 10, 1161-1172
12. 9-tetrahydrocannabinol on human breast cancer cells Oncogene 2008, 27, 5033-5044
13. Laezza, C.; Pisanti, S.; Crescenzi, E.; Bifulco, M. Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells FEBS Lett. 2006, 580, 6076-6082
14. Qamri, Z.; Preet, A.; Nasser, M. W.; Bass, C. E.; Leone, G.; Barsky, S. H.; Ganju, R. K. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer Mol. Cancer Ther. 2009, 8, 3117-3129
15. Oesch, S.; Walter, D.; Wachtel, M.; Pretre, K.; Salazar, M.; Guzmán, M.; Velasco, G.; Schäfer, B. W. Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma Mol. Cancer Ther. 2009, 8, 1838-1845
16. Olea-Herrero, N.; Vara, D.; Malagarie-Cazenave, S.; Diaz-Laviada, I. Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-methanandamide and JWH-015: involvement of CB2 Br. J. Cancer 2009, 101, 940-950
17. Han, S.; Thatte, J.; Buzard, D. J.; Jones, R. M. Therapeutic utility of cannabinoid receptor type 2 (CB2) selective agonists J. Med. Chem. 2013, 56, 8224-8256
18. Sánchez, C.; de Ceballos, M. L.; Gómez del Pulgar, T.; Rueda, D.; Corbacho, C.; Velasco, G.; Galve-Roperh, I.; Huffman, J. W.; Ramón y Cajal, S.; Guzmán, M. Inhibition of glioma growth in vivo by selective activation of the CB 2 cannabinoid receptor inhibition of glioma growth in vivo by selective activation of the CB 2 Cancer Res. 2001, 61, 5784-5789
19. Duntsch, C.; Divi, M. K.; Jones, T.; Zhou, Q.; Krishnamurthy, M.; Boehm, P.; Wood, G.; Sills, A.; Moore, B. M. Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma J. Neurooncol. 2006, 77, 143-152
20. Palazuelos, J.; Aguado, T.; Egia, A.; Mechoulam, R.; Guzmán, M.; Galve-Roperh, I. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation FASEB J. 2006, 20, 2405-2407
21. Pertwee, R. G. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities Philos. Trans. R. Soc., B 2012, 367, 3353-3363
22. Chiorean, R.; Braicu, C.; Berindan-Neagoe, I. Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth? Breast 2013, 22, 1026-1033
23. Abramson, V. G.; Lehmann, B. D.; Ballinger, T. J.; Pietenpol, J. A. Subtyping of triple-negative breast cancer: implications for therapy Cancer 2014, 1-9
24. Hoeferlin, L. A.; E.Chalfant, C. E.; Park, M. A. Challenges in the treatment of triple negative and HER2-overexpressing breast cancer J. Surg. Sci. 2013, 1, 3-7
25. Foulkes, W. D.; Smith, I. E.; Reis-Filho, J. S. Triple-negative breast cancer N. Engl. J. Med. 2010, 363, 1938-1948
26. Hudis, C. A.; Gianni, L. Triple-negative breast cancer: an unmet medical need Oncologist 2011, 16, 1-11
27. Engebraaten, O.; Vollan, H. K. M.; Børresen-Dale, A.-L. Triple-negative breast cancer and the need for new therapeutic targets Am. J. Pathol. 2013, 183, 1064-1074
28. Caffarel, M. M.; Andradas, C.; Pérez-Gómez, E.; Guzmán, M.; Sánchez, C. Cannabinoids: a new hope for breast cancer therapy? Cancer Treat. Rev. 2012, 38, 911-918
29. Morales, P.; Vara, D.; Goméz-Canas, M.; Zúniga, M. C.; Olea-Azar, C.; Goya, P.; Fernández-Ruiz, J.; Díaz-Laviada, I.; Jagerovic, N. Synthetic cannabinoid quinones: preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity Eur. J. Med. Chem. 2013, 70, 111-119
30. Cumella, J.; Hernández-Folgado, L.; Girón, R.; Sánchez, E.; Morales, P.; Hurst, D. P.; Gómez-Canas, M.; Gómez-Ruiz, M.; Pinto, D. C. G. A.; Goya, P.; Reggio, P. H.; Martin, M. I.; Fernández-Ruiz, J.; Silva, A. M. S.; Jagerovic, N. Chromenopyrazoles: non-psychoactive and selective CB1 cannabinoid agonists with peripheral antinociceptive properties ChemMedChem 2012, 7, 452-463
31. Wu, A.; Duan, Y.; Xu, D.; Penning, T. M.; Harvey, R. G. Regiospecific oxidation of polycyclic aromatic phenols to quinones by hypervalent iodine reagents Tetrahedron 2010, 66, 2111-2118
32. Magdziak, D.; Rodriguez, A. A.; Van De Water, R. W.; Pettus, T. R. R. Regioselective oxidation of phenols to o-quinones with o-iodoxybenzoic acid (IBX) Org. Lett. 2002, 285-288
33. Harvey, R. G.; Dai, Q.; Ran, C.; Penning, T. M. Synthesis of the o-quinones and other oxidized metabolites of polycyclic aromatic hydrocarbons implicated in carcinogenesis J. Org. Chem. 2004, 69, 2024-2032
34. Barontini, M.; Bernini, R.; Crisante, F.; Fabrizi, G. Selective and efficient oxidative modifications of flavonoids with 2-iodoxybenzoic acid (IBX) Tetrahedron 2010, 66, 6047-6053
35. Ekins, S.; Waller, C. L.; Swaan, P. W.; Cruciani, G.; Wrighton, S. A.; Wikel, J. H. Progress in predicting human ADME parameters in silico J. Pharmacol. Toxicol. Methods 2000, 44, 251-272
36. Van de Waterbeemd, H.; Gifford, E. ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discovery 2003, 2, 192-204
37. Jorgensen, W. L.; Duffy, E. M. Prediction of drug solubility from structure Adv. Drug Delivery Rev. 2002, 54, 355-366
38. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 2001, 44, 235-249
39. Metzger-Filho, O.; Tutt, A.; de Azambuja, E.; Saini, K. S.; Viale, G.; Loi, S.; Bradbury, I.; Bliss, J. M.; Azim, H. A.; Ellis, P.; Di Leo, A.; Baselga, J.; Sotiriou, C.; Piccart-Gebhart, M. Dissecting the heterogeneity of triple-negative breast cancer J. Clin. Oncol. 2012, 30, 1879-1887
40. Criscitiello, C.; Azim, H. A., Jr.; Schouten, P. C.; Linn, S. C.; Sotiriou, C. Understanding the biology of triple-negative breast cancer Ann. Oncol. 2012, 23 (Suppl. 6) vi13-vi18
41. Rocha, F. C. M.; Dos Santos Júnior, J. G.; Stefano, S. C.; da Silveira, D. X. Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas J. Neurooncol. 2014, 116, 11-24
42. 9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme Br. J. Cancer 2006, 95, 197-203
43. Anighoro, A.; Bajorath, J.; Rastelli, G. Polypharmacology: challenges and opportunities in drug discovery J. Med. Chem. 2014, 57, 7874-7887
44. Gediya, L. K.; Njar, V. C. O. Promise and challenges in drug discovery and development of hybrid anticancer drugs Expert Opin. Drug Discovery 2009, 4, 1099-1111
45. Kogan, N. M.; Rabinowitz, R.; Levi, P.; Gibson, D.; Sandor, P.; Schlesinger, M.; Mechoulam, R. Synthesis and antitumor activity of quinonoid derivatives of cannabinoids J. Med. Chem. 2004, 47, 3800-3806
46. Gorrini, C.; Harris, I. S.; Mak, T. W. Modulation of oxidative stress as an anticancer strategy Nat. Rev. Drug Discovery 2013, 12, 931-947
47. Ross, R. A. The enigmatic pharmacology of GPR55 Trends Pharmacol. Sci. 2009, 30, 156-163
48. Pertwee, R. G. GPR55: a new member of the cannabinoid receptor clan? Br. J. Pharmacol. 2007, 152, 984-986
49. Ford, L. A.; Roelofs, A. J.; Anavi-Goffer, S.; Mowat, L.; Simpson, D. G.; Irving, A. J.; Rogers, M. J.; Rajnicek, A. M.; Ross, R. A. A role for L-α-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells Br. J. Pharmacol. 2010, 160, 762-771
50. Bylund, D.; Toews, M. Radioligand binding methods-practical guide and tips Am. J. Physiol. 1993, 265, L421-L429